WhaleCreep

Avidity Partners Management LP 13F holdings, Q2 2023

Hedge fundSEC filingsCompare with another fundHoldings as of 2023-06-30, filed 2023-08-14

Avidity Partners Management LP disclosed 93 US equity positions worth $2.9bn in its Q2 2023 13F filing. Its largest position is BDX at 3.7% of the reported book, followed by KRTX and JAZZ. Versus Q1 2023 it opened 30 new positions, added to 17, reduced 43 and exited 20.

$2.9bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
93
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
3.7%
Largest position
The largest single position as a share of the reported equity book.
28.1%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
57
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2023: 30 new, 17 added, 43 reduced, 20 exited

50 of 93
BDX BECTON DICKINSON & COHealthcare3.7%$105m398,050+38%added
KRTX KARUNA THERAPEUTICS INC–3.3%$95.9m442,200+9.5%added
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare3.0%$87.1m702,778+3.7%added
GEHC GE HEALTHCARE TECHNOLOGIES IHealthcare3.0%$84.9m1.05m–new
THC TENET HEALTHCARE CORPHealthcare2.8%$80.6m990,500−33%reduced
ARGX ARGENX SEHealthcare2.5%$71.8m184,300−34%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare2.5%$70.2m2.99m−19%reduced
SGRY SURGERY PARTNERS INCHealthcare2.4%$70.0m1.55m−54%reduced
ABBV ABBVIE INCHealthcare2.4%$69.8m518,400–new
ARVN ARVINAS INCHealthcare2.4%$68.8m2.77m−35%reduced
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare2.3%$65.8m2.33m−20%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.2%$62.7m665,316−18%reduced
LLY ELI LILLY & COHealthcare2.2%$62.4m133,000–new
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.1%$60.1m2.87m−26%reduced
UHS UNIVERSAL HLTH SVCS INCHealthcare2.0%$58.4m370,100−45%reduced
BIO BIO RAD LABS INCHealthcare2.0%$57.9m152,600−31%reduced
COR CENCORA INCHealthcare2.0%$57.7m300,000+137%added
PACB PACIFIC BIOSCIENCES CALIF INHealthcare2.0%$57.7m4.34m+14%added
LEGN LEGEND BIOTECH CORPHealthcare1.9%$55.1m798,900−29%reduced
BIIB BIOGEN INCHealthcare1.7%$49.6m174,000+35%added
AKROEUR AKERO THERAPEUTICS INC–1.7%$47.9m1.02m−58%reduced
CUREVAC N V no ticker–1.6%$44.8m4.30m+21%added
ACHC ACADIA HEALTHCARE COMPANY INHealthcare1.5%$43.8m550,000−53%reduced
PCVX VAXCYTE INCHealthcare1.5%$43.7m875,000+72%added
MCK MCKESSON CORPHealthcare1.5%$43.2m101,200–new
APLSUSD APELLIS PHARMACEUTICALS INC–1.5%$42.7m468,700–new
BSX BOSTON SCIENTIFIC CORPHealthcare1.5%$42.5m785,700−7.6%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.5%$41.5m900,700−58%reduced
PFE PFIZER INCHealthcare1.4%$41.0m1.12m–new
IMVT IMMUNOVANT INCHealthcare1.4%$39.6m2.08m+100%added
AXSM AXSOME THERAPEUTICS INC.Healthcare1.4%$39.2m545,000−12%reduced
IMGNEUR IMMUNOGEN INC–1.3%$37.7m2.00m–new
ZTS ZOETIS INCHealthcare1.3%$37.4m217,000−47%reduced
PRTA PROTHENA CORP PLCHealthcare1.3%$36.5m535,000−50%reduced
VIR VIR BIOTECHNOLOGY INCHealthcare1.2%$35.0m1.43m−13%reduced
IMCR IMMUNOCORE HLDGS PLCHealthcare1.2%$34.5m575,000−25%reduced
SRPT SAREPTA THERAPEUTICS INCHealthcare1.2%$34.1m297,500−28%reduced
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.2%$33.0m925,000−47%reduced
BHVN BIOHAVEN LTDHealthcare1.1%$31.7m1.32m−11%reduced
RVMD REVOLUTION MEDICINES INCHealthcare1.0%$28.8m1.07m−20%reduced
PRVA PRIVIA HEALTH GROUP INCHealthcare1.0%$28.2m1.08m–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare1.0%$27.9m1.95m−4.8%reduced
BAX BAXTER INTL INCHealthcare1.0%$27.6m604,700–new
FUSION PHARMACEUTICALS INC no ticker–0.9%$26.6m5.70m0.0%held
RCKT ROCKET PHARMACEUTICALS INCHealthcare0.9%$26.3m1.33m+6.6%added
2655787D BLUEPRINT MEDICINES CORP–0.9%$26.2m415,000–new
EDIT EDITAS MEDICINE INCHealthcare0.9%$24.7m3.00m–new
VTYXUSD VENTYX BIOSCIENCES INC–0.8%$22.7m692,500−64%reduced
NTRA NATERA INCHealthcare0.7%$21.1m432,900+73%added
LNTH LANTHEUS HLDGS INCHealthcare0.7%$20.6m245,100–new

Exited since Q1 2023

20 rows
MRK MERCK & CO. INC2.1%$63.8m
OPHTEUR IVERIC BIO INC1.5%$45.5m
ABT ABBOTT LABORATORIES1.2%$35.8m
BLU BELLUS HEALTH INC NEW1.1%$32.8m
ICLR ICON PLC1.0%$30.5m
BMRN BIOMARIN PHARMACEUTICAL INC1.0%$29.2m
AVTR AVANTOR INC0.8%$23.8m
RNAGBP AVIDITY BIOSCIENCES INC0.6%$19.4m
ARQT ARCUTIS BIOTHERAPEUTICS INC0.6%$17.9m
DXCM DEXCOM INC0.6%$17.2m
BBIO BRIDGEBIO PHARMA INC0.6%$16.6m
TWST TWIST BIOSCIENCE CORP0.4%$12.4m
CYTK CYTOKINETICS INC0.3%$8.9m
KNTEUSD KINNATE BIOPHARMA INC0.2%$7.3m
GERN GERON CORP0.2%$4.6m
SGMOQ SANGAMO THERAPEUTICS INC0.1%$4.3m
PRAXIS PRECISION MEDICINES I no ticker0.1%$3.5m
CYTEIR THERAPEUTICS INC no ticker0.1%$3.2m
BCAB BIOATLA INC0.05%$1.6m
REUNION NEUROSCIENCE INC no ticker0.0%$104k

Sector mix

  • Healthcare80.8%
  • Unclassified19.2%
  • Technology0.02%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters